I-MAK Defends ‘Patent Thicket’ Claims In Response To Thom Tillis Letter
The Organization Was Accused By The Senator Of Peddling Inaccuracies
The Initiative for Medicines, Access & Knowledge has responded to criticisms leveled by North Carolina senator Thom Tillis at a report it published in 2018. The report accuses pharmaceutical firms of using patent thickets to suppress generic and biosimilar competition in the US market.
You may also be interested in...
US Senators Urge PTO’s Vidal To Tackle Pharma Patent Thickets
A bipartisan group of senators has written to the US Patent and Trademark Office, urging it to tackle the impact of patent thickets on the generic and biosimilar drug industries.
Teva Pounces On US Revlimid Opportunity With Four Strength-Offering
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.
US FDA, PTO Pulled Into Debate Over Patents And Drug Pricing
Senator Tillis requests the two agencies conduct an independent analysis of I-MAK data and the ‘false narrative’ that patents are to blame for high drug prices.